Directions of Immunotherapy for Non-Small-Cell Lung Cancer Treatment: Past, Present and Possible Future.

Int J Mol Sci · 2025 · PMC12652349 · PMID 41303538

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

16.9 months; HR = 0.87) compared with atezolizumab monotherapy, these differences did not reach statistical significance [ 69 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.